EP Patent

EP3828172A1 — Dual mechanism inhibitors for the treatment of disease

Assigned to Alcon Inc · Expires 2021-06-02 · 5y expired

What this patent protects

Compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) acting to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods compri…

USPTO Abstract

Compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) acting to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Drugs covered by this patent

Patent Metadata

Patent number
EP3828172A1
Jurisdiction
EP
Classification
—
Expires
2021-06-02
Drug substance claim
No
Drug product claim
No
Assignee
Alcon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.